
Syros Updates on SELECT-AML-1 Phase 2 Trial
Syros Pharmaceuticals (NASDAQ: SYRS) has announced it will halt enrollment in the SELECT-AML-1 Phase 2 trial, which is assessing the triplet combination of tamibarotene, venetoclax, and azacitidine versus the doublet regimen of venetoclax and azacitidine for newly diagnosed, unfit AML…













